Meeting
2024 ASCO Genitourinary Cancers Symposium
Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).
Authors
Regina Barragan-Carrillo
City of Hope Comprehensive Cancer Center, Duarte, CA
Regina Barragan-Carrillo , Neal Shiv Chawla , Nicholas Salgia , Luis A Meza , Zeynep Busra Zengin , Xiaochen Li , Nazli Dizman , Hedyeh Ebrahimi , Joann Hsu , Daniela V. Castro , Benjamin D. Mercier , Tanya B. Dorff , Abhishek Tripathi , Cristiane Decat Bergerot , Paulo Gustavo Bergerot , Alex Chehrazi-Raffle , Sumanta Kumar Pal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
06049576
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr TPS491)
DOI
10.1200/JCO.2024.42.4_suppl.TPS491
Abstract #
TPS491
Poster Bd #
M12
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients.
First Author: Ana-Alicia Beltran-Bless
Poster
2022 ASCO Annual Meeting
Prognostic factors for patients with advanced renal cell carcinoma (aRCC) in the era of first-line (1L) treatment with immune checkpoint inhibitors (ICIs).
First Author: Charlene Mantia
Poster
2021 ASCO Annual Meeting
Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
First Author: Chun Loo Gan
Poster
2024 ASCO Genitourinary Cancers Symposium
Real world outcomes of first line (1L) nivolumab and ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC): An update from the International mRCC Database Consortium (IMDC).
First Author: Connor Wells